LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Aandelen Lijst・Immunocore Holdings PLC ADR

Immunocore Holdings PLC ADR

Gesloten

28.33 2.09

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

27.75

Max

28.44

Belangrijke statistieken
By Trading Economics
Inkomsten	43M 13M
Verkoop	29M 107M
EPS	0.25
Winstmarge	12.139
Werknemers	524
EBITDA	16M 8.2M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+122.21% upside

Dividenden
By Dow Jones
Volgende Winsten	6 aug 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	18M 1.5B
Vorige openingsprijs	26.24
Vorige sluitingsprijs	28.33

Technische score

By Trading Central

Vertrouwen

Weak Bearish Evidence

27.895 / 30.16 Steun & Weerstand

Immunocore Holdings PLC ADR Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

18 mei 2026, 23:10 UTC

Populaire aandelen

Stocks to Watch: Agilysys, XP

18 mei 2026, 18:44 UTC

Belangrijke Marktbewegers

Claritev Shares Recover After Comments About DOJ

18 mei 2026, 23:55 UTC

Winsten

Review & Preview: Earnings' Last Gasp -- Barrons.com

18 mei 2026, 23:47 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

18 mei 2026, 23:47 UTC

Marktinformatie

Nikkei May Rise on Hopes for U.S.-Iran Deal -- Market Talk

18 mei 2026, 23:37 UTC

Marktinformatie

Gold Rises Amid Hopes for U.S.-Iran Peace Deal -- Market Talk

18 mei 2026, 22:31 UTC

Acquisities, Fusies, Overnames

Lens Technology Ju Teng International Shares to Resume Trading on Hong Kong Exchange on May 19

18 mei 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Lens Technology: Acquisition of Remaining Ju Teng International Shares to Cost HK$1.91B

18 mei 2026, 22:30 UTC

Acquisities, Fusies, Overnames

Lens Technology to Make Offer for Remainder Shares of Ju Teng International Only After Completion of Stake Purchase

18 mei 2026, 22:25 UTC

Acquisities, Fusies, Overnames

Lens Technology to Acquire 333.71M Ju Teng International Shares for HK$2.20 Each

18 mei 2026, 22:24 UTC

Acquisities, Fusies, Overnames

Lens Technology to Acquire 27.81% Stake in Ju Teng International for HK$734.17M

18 mei 2026, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

18 mei 2026, 20:50 UTC

Marktinformatie

Acquisities, Fusies, Overnames

Financial Services Roundup: Market Talk

18 mei 2026, 20:25 UTC

Winsten

Correct: XP 1Q Total Client Assets BRL1.53T

18 mei 2026, 20:23 UTC

Winsten

XP 1Q Total Client Assets BRL1.53B

18 mei 2026, 20:19 UTC

Winsten

XP 1Q Adj EPS BRL2.49 >XP

18 mei 2026, 20:19 UTC

Winsten

XP 1Q Rev BRL4.73B >XP

18 mei 2026, 19:10 UTC

Marktinformatie

Oil Presses Higher With No Hormuz Reopening in Sight -- Market Talk

18 mei 2026, 19:00 UTC

Winsten

5 Stocks with 5% Yields and Market-Beating Returns -- Barrons.com

18 mei 2026, 18:52 UTC

Marktinformatie

U.S. Natural Gas Futures Gain As Weather Heats Up -- Market Talk

18 mei 2026, 18:17 UTC

Marktinformatie

Acquisities, Fusies, Overnames

NextEra's Dominion Acquisition Unlikely to Spur Wider Utility Consolidation -- Market Talk

18 mei 2026, 17:22 UTC

Marktinformatie

Tokenized Assets Expected to be Over $1T By 2030 -- Market Talk

18 mei 2026, 16:57 UTC

Acquisities, Fusies, Overnames

The Long Regulatory Road Ahead for the NextEra-Dominion Deal -- Barrons.com

18 mei 2026, 16:57 UTC

Marktinformatie

Global Energy Roundup: Market Talk

18 mei 2026, 16:57 UTC

Marktinformatie

Commodities Higher as Traders Want Physical Assets -- Market Talk

18 mei 2026, 16:54 UTC

Acquisities, Fusies, Overnames

Vinci Doesn't Set Out Financial Details of Deal

18 mei 2026, 16:50 UTC

Acquisities, Fusies, Overnames

Vinci: Acquisition of New Brunswick-Based Group Stregthens Presence in Eastern Canada

18 mei 2026, 16:49 UTC

Acquisities, Fusies, Overnames

Vinci: Modern Group is Roadwork, Civil Engineering Specialist

18 mei 2026, 16:49 UTC

Acquisities, Fusies, Overnames

Vinci: Modern Group Made Revenue of Around 50 Mln Euros Last Year

18 mei 2026, 16:48 UTC

Acquisities, Fusies, Overnames

Vinci Buys Canada's Modern Group of Companies

Peer Vergelijking

Prijswijziging

Immunocore Holdings PLC ADR Prognose

Koersdoel

By TipRanks

122.21% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 62.33 USD 122.21%

Hoogste 100 USD

Laagste 33 USD

Gebaseerd op 10 Wall Street-analisten die 12-maands prijsdoelen bieden voor Immunocore Holdings PLC ADR - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

10 ratings

Buy

Hold

Sell

Gebaseerd op 10 analisten die aandelenratings hebben gegeven aan Immunocore Holdings PLC ADR - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

27.895 / 30.16Steun & Weerstand

Recent bearish events outweigh bullish events.

There is one bearish event.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.